How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about tafamidis

Marketing authorisation indication

2.1

Tafamidis (Vyndaquel, Pfizer) is indicated for 'the treatment of wild-type or hereditary transthyretin amyloidosis in adults with cardiomyopathy (ATTR-CM)'.

Price

2.3

The list price is £10,685.00 for 30 capsules of 61 mg tafamidis (excluding VAT; BNF online, accessed January 2024).

2.4

The company has a commercial arrangement, which would have applied if tafamidis had been recommended.